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Cornelia de Lange syndrome (CdLS) is a rare disease affecting multiple organs and systems
during development. Mutations in the cohesin loader, NIPBL/Scc2, were first described and
are the most frequent in clinically diagnosed CdLS patients. The molecular mechanisms
driving CdLS phenotypes are not understood. In addition to its canonical role in sister
chromatid cohesion, cohesin is implicated in the spatial organization of the genome. Here, we
investigate the transcriptome of CdLS patient-derived primary fibroblasts and observe the
downregulation of genes involved in development and system skeletal organization, providing
a link to the developmental alterations and limb abnormalities characteristic of CdLS patients.
Genome-wide distribution studies demonstrate a global reduction of NIPBL at the NIPBL-
associated high GC content regions in CdLS-derived cells. In addition, cohesin accumulates at
NIPBL-occupied sites at CpG islands potentially due to reduced cohesin translocation along
chromosomes, and fewer cohesin peaks colocalize with CTCF.
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Cornelia de Lange syndrome (CdLS; OMIM 122470,300590, 610759, 300882, 614701), also known asBrachmann-de Lange syndrome), is a rare, sporadic, and
genetically heterogeneous autosomal- or X-linked-dominant dis-
order affecting multiple organs and systems during development
(reviewed in refs. 1,2). Developmental delay and intellectual dis-
ability are typically observed. The most clinically consistent and
recognizable findings in CdLS patients are the facial features, limb
abnormalities, small stature, and neurodevelopmental anomalies.
From a molecular point of view, pathogenic variants in SMC1A,
SMC3, RAD21 (cohesin core subunits), NIPBL (cohesin loader),
and HDAC8 (cohesin deacetylase) can be identified in individuals
with clinically diagnosed CdLS3–12. About 65% of CdLS cases
have a heterozygous mutation in NIPBL, while mutations in the
other four genes account for a further 11% of patients13,14. The
molecular mechanisms of CdLS are not well understood, although
the patient phenotypes suggest that the function of cohesin and
NIPBL in chromatin structure becomes deregulated, thereby
affecting gene transcription. Mutations in genes encoding chro-
matin regulators such as ANKRD1115,16, KMT2A17, AFF418, and
BRD419,20 are also associated with a CdLS-like disorder.
Cohesin is an evolutionarily conserved ring-shaped protein
complex (reviewed in refs. 21,22) that encircles pairs of replicated
chromosomes, known as sister chromatids, allowing recognition
of the sister chromatids for segregation during both mitosis and
meiosis23,24. Sister chromatid cohesion mediated by cohesin is
essential for faithful chromosome segregation during cell
divisions25–27. Cohesin is also important for the repair of DNA
double-strand breaks through homologous recombination by
ensuring proximity of sister chromatids, and it helps regulate
chromatin structure, forming tissue and developmental specific
chromatin structures that serve to mediate long-range
interactions28–33.
The core of the cohesin complex is a ring-shaped heterotrimer
formed by evolutionarily conserved subunits: two SMC (struc-
tural maintenance of chromosomes) proteins SMC1A and SMC3
and the kleisin protein RAD21 (also called MDC1 or
SCC1)23,24,34. SMC proteins are long polypeptides that dimerize
and are connected by the kleisin RAD21 subunit at the ATPase
heads, forming a tripartite ring-like structure. Cohesin association
with chromatin is regulated by the HAWKs proteins (HEAT
repeat containing proteins Associated With Kleisins) whose
functions are to open, close, or stabilize the cohesin ring: STAG1/
STAG2 (also called SA1/SA2), PDS5 (PDS5A or PDS5B in ver-
tebrates) and NIPBL (also called SCC2)35,36. Cohesin loading to
chromatin depends on the complex formed by NIPBL and MAU2
(also called SCC4) proteins37, which facilitates topological cohe-
sin loading in vitro by stimulating cohesin’s ATPase activity38,39.
Cohesin is loaded at specific chromosomal locations, including
centromeres and promoters of some highly transcribed
genes40–43, and is then translocated44–46 to its final retention
sites, which are predominantly positions occupied by CCCTC-
binding factor (CTCF) in the case of human chromosomes45,47.
DNA is organized in loops and topologically associated
domains (TADs) where enhancers are placed in close proximity
to promoters48, contributing to chromatin structure, gene reg-
ulation, and recombination49,50. CTCF and cohesin co‐localize
extensively in the genome51 and both proteins are enriched at
TAD boundaries45,52–60. TADs, in addition to CTCF-occupied
regions, tend to be conserved through cell types and evolution61.
Cohesin accumulates at transcription start sites (TSSs) of active
genes in the absence of CTCF45, while loss of cohesin complex
abolishes TAD formation and associated loops45,57, impairing
enhancer-promoter communication.
NIPBL also plays a role in translocating cohesin along chro-
matin fibers62,63 and an interaction between NIPBL and cohesin
after loading was consistently shown64, suggesting that NIPBL
also regulates cohesin after loading. In addition, a function for
NIPBL in the formation of TADs and loops extrusion was
suggested65 and DNA loop extrusion by the human cohesin/
NIPBL holoenzyme in vitro has recently been demonstrated66–68.
Less NIPBL or cohesin and/or reduced mobility of cohesin could
underlie CdLS pathogenesis. Here, we investigate the tran-
scriptome of CdLS patient-derived primary fibroblasts and
observe that genes associated with development and system
skeletal organization are downregulated, providing a link to the
developmental alterations and limb abnormalities characteristics
of CdLS patients. Analysis of genome-wide distribution of NIPBL
and cohesin in the same cells show reduced association of NIPBL
and redistribution of cohesin, which accumulates at NIPBL-
occupied sites where it is loaded and is reduced at cohesin-CTCF
sites. We speculate that NIPBL mutations causing CdLS affect the
loop extrusion activity of the cohesin/NIPBL holoenzyme, alter-
ing chromatin contacts that are required for proper expression of
developmental genes. A reduction in 3D chromatin interactions is
observed in CdLS-derived cells using an in silico intra-TAD loops
prediction tool and validated by 3C-qPCR.
Results
Cohesin integrity is not affected in CdLS patient-derived
fibroblasts. The integrity of the cohesin complex has frequently
been studied in cycling cells where cohesion is needed. For this
reason, we wondered whether the cohesin subunits and the
cohesin regulatory proteins are also important for non-diving
cells. To investigate this, we examined the cohesin protein levels
in cycling and in non-dividing quiescent cells (Fig. 1a lanes 1–2
and Supplementary Fig. 1b lanes 1–2). To obtain quiescent cells,
control primary fibroblast cells were grown to confluence and
nutrients were deprived (0.5% serum) in the medium. Western
blots showed similar SMC1A, RAD21, STAG1, STAG2, PDS5A,
and NIPBL protein levels in control cycling and quiescent cells
(Fig. 1a and Supplementary Fig. 1a, b). Cohesive complexes,
marked by the presence of Sororin (also called CDCA5), were
only present in cycling cells (Supplementary Fig. 1b). Remarkably,
the acetylation of SMC3 was similar in cycling and quiescent cells
indicating that non-cohesive complexes are also acetylated. In
addition, SMC1A and NIPBL genes were both widely expressed in
differentiated tissues (Supplementary Fig. 1c). These results sug-
gest that not only the core of the cohesin complex, but also their
regulators, such as PDS5 which regulates cohesin dynamics and
its loader NIPBL are required to ensure that cohesin fulfills its
role in chromatin organization.
To study the integrity of the cohesin complex in patient
samples, we isolated primary dermal fibroblast from CdLS
individuals with known heterozygous mutations in the cohesin
loader NIPBL. CdLS patients with missense mutations (P1–3 and
P5–6), one with a one-aminoacid in-frame indel (P4, N1897del),
and healthy donor of similar age as controls were used
(Supplementary Table 1). Protein extracts from primary dermal
fibroblast from four CdLS patients were prepared. Similar protein
levels of SMC1A, RAD21, STAG1, STAG2, acetyl-SMC3, and
PDS5A were observed in cycling and quiescent CdLS-derived
fibroblast (Fig. 1a and Supplementary Fig. 1a, b). NIPBL protein
levels were also similar to control cells in the NIPBL-mutated
patient-derived cells. In conclusion, the CdLS phenotypes do not
arise from a reduction in NIPBL or cohesin subunits protein
levels.
We then addressed the question of whether the pool of
chromatin-bound cohesin complex is affected by the reduction in
the function of the loader NIPBL in the CdLS-derived fibroblasts.
To this end, we performed chromatin fractionation experiments
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in CdLS patient-derived fibroblasts from two CdLS patients. No
significant differences were observed in the amount of NIPBL and
cohesin subunits on chromatin-bound fractions (Fig. 1b, CP).
Most of the NIPBL protein was found in the chromatin pellets in
control and CdLS-derived fibroblasts. NIPBL was also detected at
low levels in the nuclear-soluble fractions (NFs) in CdLS-derived
fibroblasts, but not in control cells, suggesting that NIPBL
chromatin association might be slightly altered in the former
group of cells. We can conclude that bulk DNA association of the
cohesin complex and NIPBL is not greatly affected in CdLS-
derived cells. Nevertheless, we decided to analyze SMC1A,
RAD21, and NIPBL protein localization in individual cells by
immunofluorescence. No significant differences of nuclear
SMC1A, RAD21, and NIPBL signals were detected in CdLS-
derived cells in cycling (Fig. 1c and quantification in Supple-
mentary Fig. 2a) and quiescent cells (Supplementary Fig. 2b, c).
Altogether, we can conclude that the cohesin subunits and NIPBL
are properly located at the nucleus and associated with the
chromatin in CdLS-derived cells.
The C terminus hook structure of NIPBL is responsible for
catalyzing cohesin loading and interacting with RAD2169,70.
Some missense CdLS mutations were previously mapped within
the NIPBL hook region69,70. Most of the residues mutated in the
patients in our study were also located within the NIPBL hook
region (Fig. 1d). To test whether mutated NIPBL proteins in
CdLS-derived cells perturb the interaction with RAD21 co-
immunoprecipitation experiments were performed. Similar co-
purification efficiencies were observed among RAD21 and
SMC1A upon NIPBL immunopurifications (Fig. 1e), indicating
that mutated NIPBL in CdLS-derived cells still interacts with
cohesin and SMC1A.
NIPBL stabilizes cohesin chromatin association. Regulation of
cohesin dynamics is essential for its proper function. To inves-
tigate the mobility of the chromatin-associated cohesin we ana-
lyzed cohesin dynamics using inverse fluorescence recovery after
photobleaching (iFRAP) experiments. We transfected control and
CdLS-derived cells with EGFP-RAD2171. The entire cell, except
for a small nuclear region, was photobleached and the fluores-
cence redistribution in both the bleached and unbleached regions
calculated (Fig. 2a, b). Recovery of fluorescence was faster in the
CdLS-derived cells than in the control cells, suggesting that
cohesin is less stably bound. Accordingly, recently it has been
described that impairment of the CTCF and cohesin interaction
renders cohesin more dynamic in iFRAP experiments, suggesting
that CTCF stabilizes cohesin at cohesin-CTCF sites72.
The fluorescence in the unbleached region decreases upon
photobleaching of the adjacent regions due to diffusion of the
soluble EGFP-RAD21. Therefore, the drop in mean fluorescence
intensity in the unbleached region after photobleaching was used
to calculate the amount of chromatin-bound RAD2171.
Chromatin-bound cohesin becomes destabilized, as indicated by
its lower level in CdLS-derived cells (Fig. 2c), which is around
55% of that in control cells. We conclude that the association of
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Fig. 1 Cohesin integrity and subcellular localization are not affected in CdLS-derived fibroblasts. a Comparison of protein levels of NIPBL, SMC1A,
RAD21, and acetyl-SMC3 in primary fibroblasts derived from a control and three CdLS patients (P1–3) under cycling (C) and quiescent (Q) conditions.
Actin was used as the loading control. Representative images of one experiment are shown and quantifications of three biological replicates are included in
Supplementary Fig. 1a. b The chromatin-bound levels of NIPBL, SMC1A, RAD21, STAG1, and STAG2 proteins in two CdLS patients (P2 and P4) and a
control were assessed by chromatin fractionation under cycling (C) and quiescent (Q) conditions. IN, input; CF, cytosolic fraction; NF, nuclear-soluble
fraction; CP, chromatin pellet. MEK2 (cytosol) and H3 (nuclear) were used as fractionation controls. Representative blots from one biological triplicate are
shown. c Nuclear localization of RAD21, SMC1A, and NIPBL were monitored by immunofluorescence of fibroblasts derived from a control and three CdLS
patients (P1–3). Nuclei were stained using DAPI and merge signal (blue channel+ red channel) is shown. Scale bar, 10 μm. Representative images are
depicted and quantifications from more than 3 biologically independent experiments are shown in Supplementary Fig. 2a. d Representation of the mutated
residues of NIPBL in the CdLS patient-derived cells under study using Pymol software (Pymol Molecular Graphics System Version 2.0 Schrödinger, LLC)
and the Ashyba gossypii Scc2 structure from Chao et al.69. Y2216 corresponds to the residue mutated in P1 (Y2216C) and P3 (Y2216S), N1897del in P4, and
G2081A in P5 marked as red dots. e Co-immunoprecipitation experiments between NIPBL and cohesin subunits. Similar co-purification efficiencies were
observed in RAD21 and SMC1A upon NIPBL immunopurification in control and two CdLS patient cells (P1 and P2). Rabbit IgG was used as negative control
(marked as −) for the IP. (Lower panel) Quantification of relative protein levels of RAD21 and SMC1A normalized to immunoprecipitated-NIPBL. Means
and SEMs of three independent biological replicates are shown. Two-sided unpaired student’s t-test. Control, white; P1, blue; P2, purple.
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To confirm that cohesin is more dynamic in CdLS-derived cells
than in control cells, we performed a salt extraction on chromatin
fractionations. Chromatin fractions were treated with increasing
amounts of NaCl (0.25 and 0.5 M) and the amount of remaining
RAD21 on chromatin was determined (Fig. 2d). The amount of
RAD21 associated with chromatin in the CdLS-derived cells was
around 70% less than in control cells, indicating that RAD21 was
more sensitive to salt concentrations in CdLS-derived cells. All
these results indicate that the association of cohesin with
chromatin is less stable in CdLS-derived cells suggesting that
NIPBL stabilizes cohesin on DNA.
Genes involved in development and differentiation are
deregulated in CdLS-derived cells. We next analyzed the tran-
scriptomes of primary dermal fibroblasts from CdLS individuals.
Early passages of primary dermal fibroblast from five NIPBL-
mutated CdLS patients (P2–P6) and four control donors were
used in Agilent SurePrint G3 Human Gene Expression Micro-
arrays v2 (Supplementary Data 1). A statistical analysis (FDR <
0.25 and |logFC|>0.5) identified 3224 probesets containing 2049
differentially expressed genes (DEGs, Supplementary Data 2)
(1153 upregulated and 896 downregulated), with logFC values
ranging from 5.2 to −2.4 (Fig. 3a). Moreover, 506 of the 2049
(25%) genes exhibit a >1.5-fold change.
A Gene Ontology (GO) enrichment analysis terms revealed
functional differences between the CdLS expression profile
compared to control cells (Fig. 3b and Supplementary Table 2).
Genes related to embryonic development were downregulated. In
contrast, GO-defined processes related to translational initiation
and mitotic processes were upregulated.
Our GO analysis showed a deregulation of genes involved in
embryonic system development and differentiation (Fig. 3c),
including genes related to central nervous system development
and differentiation (Fig. 3c, marked in blue). Among the genes
involved in neural differentiation are the protocadherins (PCDH)
which are known to be downregulated in cohesin-SA1 and Nipbl
heterozygous mice models73,74. The expression changes of several
protocadherins genes and SHC3 involved in neuron development
were validated by RT-qPCR (Fig. 3d).
HOX (Homeobox family of genes) genes encode for master
transcription factors responsible for patterning the
anterior–posterior body axis during embryonic development.
Several HOX genes proved to be deregulated in our transcriptome
analysis (Supplementary Data 2 and Fig. 3c marked in red).
Validation by RT-qPCR confirmed the upregulation of IRX2
involved in embryonic development and several genes in the
HOXB and HOXC clusters (Fig. 3e). We also corroborated the
downregulation of the genes in the HOXD cluster and the Hox-
regulated factor HAND2. HOXD genes are expressed in the
developing limb with a characteristic proximal-distal pattern.
Deletions that remove the entire HOXD gene cluster or the 5′ end
of the cluster have been associated with severe limb abnormalities,
similar to those found in CdLS patients75.
Gene expression studies do not distinguish among deregulated
genes directly link to NIPBL mutations or due to indirect secondary
effects. To elucidate between these two possibilities, we introduced
wild-type NIPBL in CdLS-derived cells from Patient 3 (Supplemen-
tary Fig. 3). Nucleofection with commercially available GFP-NIPBL
(IDN3 from Origene) resulted in 300 times overexpression of NIPBL
mRNA (Supplementary Fig. 3a). Remarkably, re-introduction of
wild-type NIPBL rescued the altered expression of central nervous
system development and differentiation genes, such as the PCDHB
family, SHC3, and MEF2C (Supplementary Fig. 3b). In addition,
70% of the tested genes (7/10) involved in embryonic system
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Fig. 2 Chromatin-bound cohesin is less stable in CdLS-derived cells. a Representatives images of an iFRAP experiment of control (C) and two CdLS
patients (P2–3) cells before (0 min) and 5, 30, and 60min after photobleaching (green channel). The entire cell, except for a small nuclear region, was
photobleached (yellow line) and the fluorescence of EGFP-RAD21 redistribution in the bleached and unbleached regions was followed by time-lapse
microscopy. b Fluorescence recovery after bleaching was quantified as the difference between bleached and unbleached nuclear regions over 1 h in one
control (C, blue) and two CdLS patients (P2, red; P3, green) and normalized to the first post-bleach frame after 2 min. Means and SEMs are shown. Control,
n= 10; P2, n= 8; P3, n= 7 cells examined over more than 3 biologically independent experiments. Two-sided unpaired student’s t-test. c The drop in mean
fluorescence intensity in the unbleached region at the first post-bleach frame was used to calculate the chromatin-bound fraction. Same cells than in (b)
were used. Means and SEMs are shown. Two-sided unpaired student’s t-test. d Chromatin fractions were prepared from cells derived from control (C) and
CdLS patient (P) derived cells and washed with 0.25 and 0.5M of NaCl containing buffer for 30min. The amount of RAD21 bound to the chromatin was
analyzed by immunoblotting. A representative experiment is shown (left panel), in which histone3 (H3) was used as a loading control. Plots of RAD21
levels in controls (white) and 3 biologically independent samples (CdLS patients P1, P2, and P3, blue) are depicted (right panel). Means and SEMs are
shown. Two-sided unpaired student’s t-test.
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development recovered the gene expression similar to control cells
(Supplementary Fig. 3c, marked in blue). In conclusion, our results
suggest that deregulation of most of the embryonic and central
nervous system genes observed in CdLS-derived cells are directly
linked to NIPBL.
Strikingly, we found the same gene expression deregulation of
PCDH and HOX genes in two patients with mutation in the
SMC1A cohesin subunit (Supplementary Fig. 4), suggesting that
the transcriptome changes observed in NIPBL-mutated CdLS
patients could be extended to patients bearing other mutations.
Genome-wide distribution of NIPBL in CdLS-derived cells.
Cohesin distribution on chromatin is usually a good readout for
its contribution to 3D genome organization and gene regulation.
To gain insight into the genome-wide distribution of cohesin and
NIPBL we performed ChIP-sequencing experiments. Several
commercial NIPBL antibodies were validated to select the best
available antibody for ChIP-seq (Supplementary Fig. 5). NIPBL
antibody (3B9) from Novus gave the best immunoprecipitation
efficiency and had the expected localization in the nucleus by
immunofluorescence, so we used this antibody for the ChIP-seq
experiments. To be able to quantitatively compare the profiles
obtained in fibroblasts from patients and healthy donors, we
carried out a quantitative spike-in ChIP-seq experiment. We
identified 75,872 NIPBL sites in control cells (Supplementary
Data 3). Representation of the NIPBL peaks around two genomic
regions, with and without densely packed genes regions, are
shown (Fig. 4a). NIPBL sites were previously reported43 as being
most frequently found at gene promoters. We detected 8372
(11%) NIPBL peaks at promoters (Fig. 4b) and considering an
average of 20,000 genes in the human genome, we can conclude
that almost half of the gene promoters are occupied by NIPBL.
We also found 33% of NIPBL peaks to be located near enhancers
(Fig. 4b). Remarkably, the most important feature is that NIPBL
colocalized with DNA regions with high GC content (GC > 60%).
Around 67% of NIPBL peaks appeared in high GC regions
(Fig. 4b), including 38% (19,536 NIPBL peaks) in CpG islands.
The human genome is estimated to contain around 30,000 CpG
islands, meaning that 65% of all CpG islands are occupied by
NIPBL. We found that NIPBL peaks at CpG islands coincide with
promoters (39%) and with enhancers (29%) (Fig. 4c). CpG
islands tend to accumulate at promoters, enhancers, and devel-
opmental gene clusters76. By examining the NIPBL peak dis-
tribution with respect to the chromosomal distance (Fig. 4d), we
observed that many NIPBL peaks appear close together, with







































































































































































































Fig. 3 Genes involved in development and differentiation are deregulated in CdLS patient-derived cells. a Volcano plot representation of gene
expression changes between control and CdLS-derived fibroblasts. Significantly downregulated and upregulated genes are indicated in red. Green, blue, and
gray show non-significant differential genes. b Gene ontology (GO) enrichment analyses reveal biological processes that are downregulated and
upregulated in CdLS-derived fibroblasts (blue bars). c Representation of the log-fold changes in expression of genes related to developmental processes
(black bars). Genes involved in embryonic system development and differentiation are marked in red, those involved in nervous system development are
marked in blue. Two-sided unpaired student’s t-test (**p < 0.01; *p < 0.05). d, e The expression levels of some nervous system development genes (d) and
embryonic development genes (e) were analyzed in a control (C, white) and three CdLS patient-derived fibroblasts (P1, blue; P2, purple; P3, green) by
reverse transcription-qPCR. The graphs show the amount of transcript of each gene relative to that in the control. Means and SEMs were calculated from
biological triplicates. Two-sided unpaired student’s t-test (****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05).
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Quantitative comparison between the NIPBL ChIP-seq ana-
lyses in control and CdLS-derived fibroblasts from Patient
3 showed a great loss of NIPBL signal in the patient (Fig. 4e, f;
Supplementary Data 3). We identified 20,428 NIPBL sites in
CdLS-derived cells which correspond to a reduction of 73% of the
called peaks compared with the control. Validation by NIPBL
ChIP-qPCR was done in other three patients (P1, P2, and P4) in 5
regions including the HOXB, C, and D (EVX2 position) clusters
(Supplementary Fig. 6). We conclude that mutated NIPBL in
CdLS patients associates with chromatin less efficiently than it
does in control cells.
From the genes differentially expressed in CdLS-derived cells
(Supplementary Data 2), 40% contained NIPBL at their
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of NIPBL peaks at the HOX and protocadherin clusters (Fig. 4g).
Accumulation of NIPBL was also detected in other gene cluster
regions such as alpha-globin, histone HIST1, keratin II, IRXA,
and IRXB. In general, these clusters are rich in CpG islands, and
chromatin-bound NIPBL is associated with the presence of CpG
islands. Unlike the alpha-globin cluster, which contains CpG
islands, the beta-globin cluster is an A+ T rich region, does not
contain CpG islands and we did not detect NIPBL chromatin
association (Fig. 4g).
Since CpG dinucleotides are regulated by DNA methylation,
we wondered whether DNA methylation patterns changed in our
CdLS-derived cells. In genome-wide DNA methylation analysis,
we found 123 differential methylation positions (DMPs) between
controls and CdLS-derived cells (Supplementary Data 4). DMPs
at promoters are those that can lead to a change in gene
expression, and we identified only 13 of these (Fig. 4h upper panel
and Supplementary Data 4) which included four DMPs at
promoters of HOX genes. Pyrosequencing validation of the DNA
methylation changes in three controls and four patients
confirmed the decrease in the differential DNA methylation
regions (DMR) at HOXB3 and HOXC4,5,6 promoters in CdLS-
derived cells (Fig. 4h lower panel). The decrease in DNA
methylation is associated with an increase in gene expression, as
shown in (Fig. 3e). In conclusion, the overall differences in gene
expression in CdLS-derived cells are not due to the defective
DNA methylation of the promoters of the corresponding genes,
consistent with the fact that most CpG islands at promoters are
demethylated. However, in the HOXB-C genes, DNA methylation
may also contribute to the differential expression detected.
Genome-wide distribution of cohesin in CdLS patient-derived
fibroblasts. Since NIPBL is the cohesin loader we performed
SMC1A ChIP-sequencing experiments with a control and two
CdLS-derived fibroblasts (P3 and P4). We identified 22,957
SMC1A peaks in the control and 26,190 in the P3 CdLS-derived
cells (Supplementary Data 5). Our SMC1A ChIP-seq data overlap
closely with RAD21 ChIP-seq data from Encode (Fig. 5a, b).
Venn diagrams showed a high degree (91% of sites) of overlap of
SMC1A and RAD21 sites, as expected (Fig. 5b), while the overlap
with NIPBL was reduced to 9.7% sites. Consistently, NIPBL peaks
overlap only slightly with RAD21 and CTCF from Encode (21%
with RAD21 and 26% with CTCF).
Although SMC1A distribution appears similar in control and
CdLS-derived cells, a careful analysis using the MaNorm
software identified 1732 differential peaks between the control
and P3 (Supplementary Data 6), of which 1082 are gained and
649 are lost (Fig. 5c). Importantly, sites where we identified
SMC1A gains are characterized by the presence of NIPBL
peaks, with 69% of all gained SMC1A peaks being co-occupied
by NIPBL (Fig. 5c). Moreover, genomic locations where we
detected SMC1A gains are also characterized by a low or absent
CTCF occupancy, a moderate DNase accessibility, and low
MNase signal (Fig. 5d, left panel). Interestingly, genomic
locations where we identified SMC1A peak gains show a
decrease in the NIPBL occupancy levels in the CdLS-derived
cells. By contrast, the SMC1A sites that are lost in the patients
are characterized by a weak NIPBL signal, a strong high CTCF
signal, and two well-defined MNase peaks flanking the CTCF
peak, which is indicative of the presence of defined cohesin-
CTCFs sites (Fig. 5d, right panel). Similar results were obtained
in the SMC1A ChIP-seq for a second patient, Patient 4
(Supplementary Fig. 7, Supplementary Data 7). An increase of
the SMC1A signal at CpG islands colocalizing with NIPBL was
observed, while reduction of the SMC1A signal mainly occurred
at cohesin-CTCF sites (Supplementary Data 8, Supplementary
Fig. 7c–e). Taken together, our results clearly indicate that the
chromatin regions, where SMC1A is gained and lost, are
structurally very different: while SMC1A tends to be gained at
NIPBL-occupied, CTCF-free, moderately accessible regions;
SMC1A tends to be lost at regions where it is usually found:
CTCF-occupied and NIPBL-free regions.
ChIP-seq shows that NIPBL is mostly found in high GC
content regions, with a subpopulation of peaks corresponding to
CpG islands. Thus, we wondered whether the differential SMC1A
peaks colocalize with NIPBL at CpG islands. This is indeed the
case, since of all SMC1A peaks that overlap with NIPBL, 85%
corresponded to CpG islands (Fig. 5e).
Since CpG islands are commonly found at promoters and
enhancers, we interrogated the genome-wide distribution of the
SMC1A differential peaks (Fig. 5f). With regards to gained peaks,
61% of the SMC1A peaks corresponded to CpG islands; and 31
and 33% overlapped with promoters and enhancers, respectively.
As expected, most of the promoter sites contained CpG islands,
while only half of the enhancers did so. By contrast, 55% of the
SMC1A lost peaks colocalized with CTCF. These results
confirmed that SMC1A gained peaks in the CdLS-derived cells
correspond mostly to NIPBL-occupied sites at CpG islands, while
peaks are lost at CTCF overlapping sites.
An increase in the SMC1A signal at NIPBL-occupied CpG
island was validated at 10 positions in two patients (Fig. 6a). Next,
we studied the gene ontology of the SMC1A differential peaks
and terms related to development and transcription were greatly
enriched (Fig. 6b, Supplementary Data 9), including HOX genes.
We validated the results by SMC1A ChIP-seq qPCR and
confirmed that SMC1A is enriched at cohesin-CTCF sites in
HOX and PCDH clusters in control and CdLS-derived cells
(Fig. 6c). SMC1A DNA binding was reduced in CdLS-derived
cells at four out of the seven HOX and three out of the
four PCDH sites tested. In conclusion, the differential SMC1A
peaks appeared close to genes related to development and
transcription.
Fig. 4 Genome-wide distribution of NIPBL in CdLS-derived cells. a Snapshots of the browser showing representatives NIPBL ChIP-seq data in control
fibroblasts in two different genomic regions. b NIPBL peaks distribution. Percentages of NIPBL peaks that colocalized with the indicated genomic features
(black, GC > 60; blue, enhancer; purple, CpG Island; green, promoters). c Pie charts showing the distribution of NIPBL peaks located at CpG islands in
promoters (red), enhancers (blue), or promoters+ enhancers (violet) and others (green). d Plot representing the NIPBL peaks distribution with respect to
the chromosome distance (pink) compared with random peak distribution (green). e Heatmap (left panel) and plot of mean read density NIPBL signals
(right panel) showing a general loss of NIPBL signal around NIPBL peaks in Patient 3-derived cells (red) compared with the control (black). f Heatmap
showing NIPBL signal distribution with respect to the DNA GC content and its presence into a CpG island and their corresponding signal in the patient (GC
content <= 60%, pink; GC content > 60%, light blue; in CpG island, light red; not in CpG Island, blue). g Snapshots of the NIPBL peaks distribution in
control (C) and CdLS Patient 3-derived cells (P3) at four gene clusters. CpG island positions are indicated in green boxes. h DNA methylation in CdLS-
derived fibroblasts. (upper panel) Volcano plot representing the DNA methylation changes in control and CdLS-derived fibroblasts (significantly
methylated samples are marked in blue and non-significant in red). Validation by bisulfite pyrosequencing was performed at six DMPs for HOXB3 (Control,
n= 3, gray; Patients, n= 3, blue) and at five for HOXC4, 5, and 6 (Control, n= 3, gray; Patients, n= 4, blue) from three independent experiments (lower
panel). Means were calculated for all the DMPs within a promoter and represented as DMRs. Two-sided unpaired student’s t-test (****p < 0.0001).
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Reduction of chromatin contacts in CdLS patient-derived
fibroblasts. Using a computational method previously
described77 we predicted 3D-looped intra-TAD structures based
on CTCF motif orientation (1D) and CTCF and cohesin ChIP-
seq binding strength data (2D). To validate the method, we
compared the in silico predicted intra-TAD loops using the data
from our control sample SMC1A ChIP-seq with published Hi-C
data for a fibroblast cell line IMR9078. We identified 7268
experimental loops for IMR90 with a median loop size of 239 kb
(IQR 290 kb) containing a CTCF motif within both their
boundaries (Supplementary Data 10). On the other hand, we
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Fig. 5 Genome-wide distribution of SMC1A in CdLS-derived cells. a Heatmap showing the signal around all SMC1A peaks in control and CdLS patient 3-
derived cells and its colocalization with CTCF and RAD21. b (left) Venn diagrams showing the overlap of genomic positions of SMC1A (dark blue) with
CTCF (light red) and RAD21 (green) (up), SMC1A (dark blue) with NIPBL (light red) (bottom) or NIPBL (dark blue) with CTCF (light blue) and RAD21
(green) (right). b (right) Bam graph showing the mean signal of NIPBL (Control, black; Patient, red), SMC1A (Control, blue; Patient, orange), CTCF (green),
and MNase (gray) around NIPBL peaks in control and CdLS patient 3-derived cells. c Heatmap comparing the signal in control and CdLS patient 3-derived
cells around differential SMC1A peaks. Signals of SMC1A, NIPBL, CTCF, DNase, and MNase genomic distribution are depicted. The heatmap is divided into
two categories, SMC1A peaks gained (pink) or lost (light blue) in the patient compared with the control. d Bam graphs showing mean signal of the
indicated proteins around gained (left) and lost (right) SMC1A genomic positions. NIPBL (Control, black; Patient, red), SMC1A (Control, blue; Patient,
orange), CTCF (green), DNase (brown), and MNase (gray). e Pie charts showing the overlap of gained (left) and lost (right) SMC1A peaks with NIPBL and
CpG islands (CGI). NIPBL, green; NIPBL&CGI, red; no NIPBL, blue; no NIPBL&CGI, violet. f Plots of percentages of SMC1A gained and lost peaks overlapping
with CpG islands (CGI, black), promoters (blue), enhancers (pink), and CTCF (green).
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229.7 kb median size (IQR 339.1 kb) (Supplementary Data 10).
Then, we quantified the in silico and experimental TADs that
reciprocally overlapped (complete match) or partially matched
(Fig. 7a, see “Methods” for more details). Most of the experi-
mental loops (around 85%) completely (38.9%) or partially
(52.9%) matched with the predicted intra-TADs (Supplementary
Fig. 8a). Among them, 65.6% of loops overlap more than 75%
(38.9% complete match and 26.5% of partial match) (Supple-
mentary Fig. 8a, b). Partially matching predicted intra-TAD loops
in the control sample were mainly located inside an experimental
loop (15.2%) or included one (27.8%); while the remaining 56.9%
correspond to predicted intra-TADs that are displaced upstream
or downstream (Supplementary Fig. 8c). These results suggest
that the intra-TAD prediction tool can recapitulate most of the
experimental TADs detected in Hi-C data, validating the use of
the computational tool for prediction of intra-TAD loops.
Next, we used the computational tool for prediction of intra-
TAD loops using the SMC1A ChIP-seq data for CdLS Patient 3
and Patient 4 and compared it with the control dataset (Fig. 7). A
total of 17,766 intra-TADs were predicted for the CdLS patients.
We found 25.3% intra-TAD loops that are different between the





























































































































































































Fig. 6 Validation of the differential SMC1A peaks by ChIP-qPCR experiments. a Cells from a control (white) and two CdLS patients (P2, blue; P3 purple)
were used in ChIP-qPCR experiments to validate the SMC1A ChIP-Seq data using primers at the indicated genes. An intergenic region was used as a
negative control (Neg −). Means and SEMs were calculated from biological triplicates (left). Two-sided unpaired student’s t-test (**p < 0.01; *p < 0.05).
Snapshots of SMC1A and NIPBL peak distributions in control (C) and CdLS patient cells (P3–4) at three validated genome regions (right). The red arrows
indicate the validated SMC1A peaks. b Gene ontology (GO) analysis reveals enriched biological processes in the SMC1A differential genomic positions in
CdLS-derived fibroblasts. c ChIP-qPCR experiments were performed to validate the SMC1A ChIP-Seq data at three regions of HOXB, two of HOXC, two of
HOXD, and four regions of the PCDHB clusters using cells from a control (white) and a CdLS patient (blue). Means and SEMs were calculated from
biological duplicates (HOX) and triplicates (PCDHB). Two-sided unpaired student’s t-test (****p < 0.0001; *p < 0.05) (left). Snapshots of SMC1A peak
distributions in control (C) and CdLS patient cells (P3–4) for the HOXB cluster (right). Red arrows indicate three validated SMC1A peaks within the HOXB
cluster.
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intra-TAD loops and 9% of partial intra-TAD loops with less
than 75% overlap (Fig. 7b and Supplementary Data 11). In
addition, control intra-TAD scores were significantly higher than
both patients while between patients no significant differences
were detected (Fig. 7c). In order to validate the data obtained with
the intra-TAD prediction tool, we performed 3C-qPCR experi-
ments in control and CdLS-derived cells from Patient 1 and
Patient 2. A 30% reduction in the 3C contacts was observed in the
CdLS-derived cells (Fig. 7d). This suggests that the intra-TAD
loops are weaker or loosen in the CdLS patients pointing out to a
less constrain chromatin organization. Alternatively, a higher
single-cell variability of intra-TAD loop formation in CdLS-






























































































































Fig. 7 Reduction of chromatin contacts in CdLS patient-derived fibroblasts. a Cartoon representing the complete (red), partial (green), and unmatched
(blue) intra-TADs (see “Methods” for more details). b Bar plot showing the percentage of the predicted intra-TAD loops from CdLS patients completely
(71.9%), partially (11.8%), or unmatching (16.3%) with the control intra-TADs. TADs with an overlap of more than 75% are considered unchanged (gray)
between the control and the patients. TADs with an overlap lower than 75% are considered different between the control and the patients (blue).
c Boxplots and violin plots representing the intra-TAD combined scores predicted for control (black), patient 3 (light blue), and patient 4 (steel blue).
Boxplots: center line, median; box limits, first and third quartiles; whiskers, 1.5× interquartile; points, outliers. Violin plots show the corresponding
probability density function. Two-sided Wilcoxon test (****p < 0.0001). d Validation of the intra-TAD loops prediction by 3C-qPCR experiments from a
control and two CdLS patients from biological triplicates. Means and SEMs are shown. Two-sided unpaired student’s t-test (***p < 0.001; **p < 0.01; *p <
0.05). Snapshot of a representative intra-TAD loops prediction is depicted (right). e A model for the differential NIPBL and cohesin genomic distribution in
CdLS patient-derived cells. Under normal conditions NIPBL (red) is enriched in regions of high GC content, including promoters, enhancers, and gene
clusters. Cohesin (green) is recruited at the NIPBL-occupied positions and reaches their final cohesin-CTCF (black) sites by DNA translocation and loop
extrusion formation (left). NIPBL chromatin association is greatly reduced in CdLS-derived cells. Defective NIPBL function might reduce cohesin DNA
translocation and/or loop extrusion kinetics. Cohesin peaks increase at the NIPBL-occupied positions and reduce at the cohesin-CTCF sites (right).
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Discussion
CdLS is a cohesinopathy, also considered recently a
transcriptomopathy17. Our data suggest that CdLS arises from a
NIPBL role independently of its cohesin-loading function. A
defect in the recently described loop extrusion function of the
cohesin-NIPBL holoenzyme66–68 could explain most of the
defects observed in CdLS (Fig. 7e). Reduced NIPBL function in
CdLS-derived cells drives accumulation of cohesin at NIPBL-
occupied sites where cohesin is likely loaded, and those cohesin
complexes do not move away to reach their final destination at
cohesin-CTCF sites. In addition, fewer cohesin peaks colocalize
with CTCF, suggesting that an alteration of the NIPBL post-
loading function affects cohesin translocation, chromatin loops,
or long-range interactions.
Cohesin loop extrusion depends on the presence of NIPBL, not
only at the start but throughout the entire process, indicating that
cohesin-NIPBL is the active loop extruding holoenzyme66.
NIPBL’s role in chromatin structure is therefore more important
than anticipated, and our results suggest that the cohesin-NIPBL
function in loop extrusion is affected in CdLS-derived cells. Since
NIPBL stimulates cohesin ATPase activity42,79,80 we propose that
mutated NIPBL in CdLS affects cohesin translocation, perhaps by
impairing stimulation of the cohesin ATPase activity. This is
consistent with ATP hydrolysis being required for relocation of
cohesin from the cohesin-loading Scc2 sites in budding yeast81. It
will be interesting to explore how the CdLS-mutated NIPBL
regulates cohesin translocation and loop extrusion formation.
The final cohesin-CTCF sites are mostly constant among tis-
sues and cell types, suggesting that they are stable cohesin binding
peaks. By contrast, in CdLS-derived cells, we observed a reduction
in the SMC1A signal at cohesin-CTCF sites, in accordance with
the less stable chromatin-bound RAD21 observed by iFRAP.
Recently, it has been shown that CTCF depletion reduced stable
chromatin binding of cohesin-STAG1, suggesting that CTCF
stabilizes cohesin-STAG1 on chromatin82. Similarly, in CdLS-
derived cells, we observed that cohesin is also more dynamic
when it does not reach CTCF sites. In addition, RAD21 is released
from chromatin at lower salt concentrations in CdLS-derived cells
(Fig. 2d), in agreement with the less stably chromatin-bound
cohesin found in CdLS-derived cells. High salt concentrations
also greatly reduced the number of DNA loops extruded by
cohesin-NIPBL66, suggesting that cohesin entraps DNA non-
topologically, or that cohesin and NIPBL interactions are salt-
sensitive. Either way, this is consistent with a reduced role for
cohesin-NIPBL holoenzyme in loop extrusion in CdLS-derived
cells. Reduced processivity of loop extrusion or the ability to
spread across chromatin will alter enhancer-promoter interac-
tions and thereby deregulate gene expression.
Around 65% of CdLS patients present pathogenic variants
in the NIPBL cohesin loader. We mainly used primary dermal
fibroblasts derived from CdLS patients with pathogenic var-
iants in the NIPBL gene. Our calibrated NIPBL ChIP-seq
showed a global reduction of the NIPBL signal in CdLS-
derived fibroblasts. This may reflect the fact that the mutated
NIPBL protein has difficulties binding to DNA, while the wild-
type NIPBL allele in the heterozygous patients retains its
ability to bind DNA. Alternatively, this might be a con-
sequence of a dominant-negative NIPBL protein struggling to
perform its function in cohesin loading, translocating cohesin
along the chromatin62 or in loop extrusion55,65–67.
Contradictory results were previously reported for NIPBL
ChIP-seq data. Some authors reported that a fraction of NIPBL
peaks colocalize with cohesin at promoters and enhancers40,83,
while others found mostly no overlap with cohesin, since NIPBL
is located at active promoters with no cohesin signal43,45. Dif-
ferent affinities among the antibodies, cross-linking problems,
and a lack of calibrated ChIP-seq data could explain many of the
discrepancies observed. For this reason, we performed calibrated
NIPBL ChIP-seq data after a deep characterization of NIPBL
antibodies. We found that NIPBL associates mostly at GC-rich
regions, including CpG islands. Promoters, enhancers, and clus-
ters of developmental genes are commonly CpG island-rich
regions76. Our results reconcile those of previous studies showing
that NIPBL colocalizes with promoter and/or enhancer and
extend the NIPBL genome-wide distribution to high GC-rich
regions.
NIPBL binds at regions with high CG content (>60%),
including (but not exclusively) CpG islands around TSS and
nearby enhancers. DNA-binding transcription factors and
developmentally important genes (including the HOX and PCDH
genes) are greatly overrepresented near clusters of three or more
CpG islands76. We observed that NIPBL colocalized with CpG
islands in the developmental gene cluster families rich in CpG
islands (Fig. 4g). A large accumulation of NIPBL peaks appear at
HOX, protocadherin, histone HIST1, keratin II, IRXA, and IRXB
clusters in control cells. Interestingly, reduced NIPBL chromatin
association in CdLS-derived cells at HOX and protocadherin
clusters correspond with the reduction in the binding of SMC1A
in the cohesin-CTCF peaks located nearby and with gene
expression deregulation of the HOX and protocadherin gene
families. Consistently, during limb development, NIPBL is
required for the regulation of long-range interactions and colli-
near expression of hox genes in zebrafish84. Appropriate spatial
and temporal expression of Hox genes is important for limb
development in all vertebrates85.
Previous studies reported on the CdLS transcriptome in lym-
phoblastoid cell lines (LCLs)86,87. Only 126 differentially
expressed genes were shared by the gene expression profiles of
NIPBL-mutated86 (1431 DEGs) and SMC1A-mutated87 (1186
DEGs) LCLs, respectively83. Similarly, no correlation with our
gene expression profile was found.
The transcriptome changes that we observed in CdLS patient-
derived fibroblasts were also found in two patients with SMC1A
mutations (Supplementary Fig. 4), suggesting that our gene
expression profile can be extended to CdLS patients with muta-
tions in other genes. This is consistent with our hypothesis that
the cohesin-NIPBL holoenzyme function in loop extrusion is the
one most affected in CdLS-derived cells. During the early stages
of embryonic development, the defective cohesin-NIPBL in
CdLS-mutated cells might provoke an alteration in the chromatin
structure, especially in some genomic regions such as those of the
developmental gene clusters. These changes in chromatin struc-
tures would be fixed in different cell types during development
and, for this reason, could be detected in the dermal fibroblast-
derived cells.
Methods
Cell culture. Primary dermal fibroblasts from individuals with CdLS and primary
dermal fibroblasts from control individuals were kindly provided by Dr J. Pie, Dr
A. Latorre-Pellicer, Dr B. Puisac, and Dr. F. Ramos of the Hospital Clínico Uni-
versitario “Lozano Blesa” from Zaragoza. The collection sample protocol was
supervised and approved by the Clinical Research Ethics Committees of the
Hospital Clínico Universitario “Lozano Blesa” from Zaragoza and of the Hospital
Universitario de Bellvitge (IDIBELL). The study design and conduct complied with
all relevant regulations regarding the use of human study participants and was
conducted in accordance with the criteria set by the Declaration of Helsinki. All
patients were informed beforehand and gave their written consent to participate in
this study. The patients used in this study present pathogenic variants in NIPBL or
SMC1A genes (Supplementary Table 1). All cells were routinely tested for myco-
plasma by PCR and maintained mycoplasma-free. Cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM+GlutaMAX) supplemented with 10% FBS.
Cycling cells were collected 24 h after replating. To obtain quiescent cells, confluent
cultures were incubated in DMEM with 0.5% FBS for 24 h. A list of oligonucleo-
tides used in this study is reported in Supplementary Table 3.
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Protein extracts and chromatin fractionation. For whole-cell extracts, cells were
collected by scraping in PBS1x buffer, counted, resuspended in lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.1), sonicated, and incubated for 1 h on
ice. Equal protein concentrations were separated by SDS-PAGE (Mini-Protean
TGX Gels 4–12% (Bio-Rad)) and analyzed by immunoblotting.
Protein was fractionated with the Nuclear Extract kit (Active Motif; 40010),
following the manufacturer’s instructions. To assess the strength of chromatin
association of the cohesin complex (Fig. 2d), chromatin fractions were obtained
with a Nuclear Extract kit (Active Motif; 40010) treated with buffer A (10 mM
HEPES, 1.5 mM MgCl2, 0.34M sucrose, 10% glycerol, 1 mM DTT, and protease
inhibitors) containing 0.25M or 0.5 M of NaCl for 30 min on ice. Solubilized
proteins were separated from insoluble chromatin by low-speed centrifugation
(4 min at 1700 × g) and washed twice with Buffer A without salt. The insoluble
fractions were analyzed by immunoblotting.
Immunoprecipitation. Immunoprecipitation of NIPBL was performed as descri-
bed in ref. 88, briefly 8 × 106 fibroblasts were resuspended in 0.5 ml lysis buffer (20
mM Hepes pH 7.6, 150 mM NaCl, 10% glycerol, 0.2% NP-40, 1 mM NaF, 1 mM
sodium butyrate, 1 mM EDTA and complete protease and phosphatase inhibitors
(Roche)) and cells were incubated 45 min at 4 °C. Chromatin and soluble fractions
were separated by centrifugation at 1000 × g for 3 min at 4 °C. The chromatin pellet
was washed 10 times by re-suspension in 1 ml lysis buffer and centrifugation at
1000 × g for 3 min at 4 °C. The chromatin pellet was then resuspended in 250 µl
nuclease buffer (lysis buffer complemented with a final concentration of 0.04 units/
µl micrococcal nuclease, 0.1 mg/ml RNase A, 20 mM CaCl2, and 0.04 µl/ml Turbo
DNase), incubated for 2 h at 4 °C and for 15 min at 37 °C. Chromatin extracts
were pre-cleared with magnetic protein-G Dynabeads® (Life Technologies) for 1 h
at 4 °C and then the supernatant was incubated with 10 µl of the specific NIPBL
antibody (3B9, Novus Biologicals H00025836-M01), and the immunocomplexes
were adsorbed onto magnetic protein-G at 4 °C overnight. The beads were washed
seven times with buffer B (25 mM Tris-HCl, 500 mM NaCl, 5 mM MgCl2, 0.5%
NP-40) and eluted with 2X SDS-PAGE loading buffer for 5 min at 95 °C.
Immunoblotting. Primary antibodies used in this study were anti-RAD21 1:500
(Abcam, ab992), anti-SMC1A 1:500 (Abcam, ab9262), anti-SMC3 1:500 (Abcam,
ab9263), anti-STAG1 1:500 (Bethyl, A302-579A), anti-STAG2 1:200 (Santa Cruz,
sc-81852), anti-histone H3 1:1000 (Abcam, ab1791), anti-MEK2 1:500 (BD,
610235), anti-nucleolin 1:500 (Santa Cruz, sc-8031), anti-AcSMC3 1:500 (MBL,
PD040), and anti-NIPBL 1:500 (KT55, Abcam, ab106768) for immunoblotting and
5 µl anti-NIPBL (3B9, Novus Biological H00025836-M01), 25 µl H-300 (Santa
Cruz, sc-98601), and 25 µl C-9 (Santa Cruz, sc-374625) for immunoprecipitation
(Supplementary Fig. 5). Custom-made rabbit polyclonal antibodies against PDS5A
(1:500) have been described89 and those for human sororin (1:500) were raised
using the recombinant protein purified from bacteria as antigen. Horseradish
peroxidase HRP-conjugated (1:10,000) secondary antibodies (Amersham Bios-
ciences) were used. Immunoblots were quantified using ImageJ software (Fiji
v1.53).
Immunofluorescence. Human fibroblasts were cultured on coverslips and fixed
with paraformaldehyde 4% for 15 min at room temperature, washed three
times with 1× PBS, and permeabilized with 0.1% of Triton X-100 in PBS for 20
min at RT. The coverslips were washed again and blocked with 1% BSA in PBS
for 1 h at RT. After blocking, cells were incubated overnight at 4 °C with the
corresponding antibody diluted in blocking solution (anti-NIPBL 3B9) 1:100,
anti-SMC1A73 1:1000, and anti-RAD21 1:100. Cells were incubated with the
secondary antibody, Cy3-labeled α-mouse (GE Healthcare) for anti-NIPBL and
Alexa 555-labeled α-rabbit (Abcam, ab150082) for anti-SMC1A and anti-
RAD21, 1:1000 for 1 h at RT. The coverslips were air-dried and 3 µl of the
mounting medium with DAPI (Vectashield, H-1200) were added. Images were
captured with a Zeiss Axio Observer Z1 inverted epifluorescence microscope
with an Apotome system equipped with an HXP 120C fluorescent lamp and a
Carl Zeiss Plan-Apochromat 63× N.A 1.40 oil objective, in conjunction with
ZEN software (blue edition, v1.0). Fluorescence was quantified using ImageJ
software (Fiji v1.53).
Photobleaching experiments: inverse fluorescence recovery after photo-
bleaching (iFRAP). Human fibroblasts were nucleofected 18 h before acquiring
microscope images with the plasmid EGFP-RAD2171 using the Amaxa® Human
Dermal Fibroblasts Nucleofector Kit (Lonza), following the manufacturer’s
instructions. Cells were grown on glass plates. One hour before imaging, the
medium was changed to one without phenol red, and 100 µg/ml of cycloheximide
was added to reduce synthesis of new GFP-tagged cohesin for experiments lasting
longer than 1 h. All iFRAP experiments used ten interactions of photobleaching at
100% transmission of 488 nm laser of the Carl Zeiss LSM880 confocal microscope,
with a 63× NA 1.4 objective with ZEN software (black edition v2.3). Cytoplasmic
and nuclear regions were bleached, leaving only half of the nuclear region
unbleached. The first post-bleach frame was acquired 60 s after photobleaching to
allow for complete equilibration of unbleached soluble GFP-cohesin across the
nucleus. Fluorescence recovery after bleaching was quantified using ImageJ
software (Fiji v1.53), considering the difference in mean intensity between bleached
and unbleached regions over 1 h. The drop in mean fluorescence intensity in the
unbleached nuclear region after photobleaching was used to calculate the
chromatin-bound fraction of EGFP-RAD2171.
Gene expression microarrays and analysis. Total RNA from the early passage
(p3) of dermal-derived fibroblasts from four healthy individuals were used as
controls and five different NIPBL-mutated CdLS patients, including two patients in
duplicate, were analyzed using Agilent SurePrint G3 Human Gene Expression
Microarrays v2 (ID 039494). The two-color labeling protocol for Microarray-Based
Gene Expression Analysis v. 6.5 (Agilent) was used. Agilent Feature Extraction
Software (FES 10.7.3.1) was used to read and process the microarray image files.
Raw data are summarized in Supplementary Data 1.
Raw data import and pre-processing steps were done with the limma
package (v4.44.3)90 in R (v4.0.2). The raw signal data were background
corrected with the normexp+ offset method considering a k value of 50 and
normalized between arrays using the quantile-normalization method. The
selection of differential expressed genes (DEG) was based on a linear model
adjusted by age stages. Two age stages were considered, individuals under and
over 15 years old. p-values were computed by moderated t-statistics using
empirical Bayes shrinkage and adjusted to control the false discovery rate using
the Benjamini and Hochberg method. Genes were considered DEG when FDR
< 0.25 and |logFC|>0.5.
Gene Ontology analysis. We used DAVID bioinformatics91 and pre-ranked GSEA
(v4.1.0)92 using the biological processes curated in the collection C5 from
MsigDB93 to search for enriched gene ontology biological processes. The log-fold
change values resulting from the DE analysis were used to rank the list of genes.
The GSEA performance was run using 1000 gene permutations, a weighted gene
enrichment statistic, and gene sets were limited to those containing between 15 and
500 genes. Gene sets with an FDR q-value lower than 0.25 were considered sig-
nificantly enriched.
RNA purification and quantitative real-time PCR (qRT-PCR) analysis. cDNAs
were prepared with the Transcriptor First Strand cDNA Synthesis Kit (Roche)
from total RNA from passages p4-p8 (NucleoSpin RNA Kit, Macherey-Nagel), and
qRT-PCR analyses were performed using the SYBR Premix Ex Taq (Takara) and a
Light Cycler 480 instrument (Roche). AnyGenes custom panels (BioNova) were
used to validate some gene expression results from the microarrays. Expression was
normalized with respect to the mean level of expression of the housekeeping genes
ACTB1, TFAP2E, ACBD3, and LETMD1. Reactions were performed in triplicate.
To investigate the effect in gene expression upon introduction of control NIPBL
(Supplementary Fig. 3), patient 3-derived fibroblast were nucleofected (Amaxa®
Human Dermal Fibroblasts Nucleofector Kit (Lonza)) with 2 µg of the commercial
plasmid IDN3 (NIPBL-GFP) (NM_015384) Human Tagged ORF Clone (Origene)
in triplicate, followed by qRT-PCR after 24 h.
Chromatin immunoprecipitation followed by sequencing and analysis. For
SMC1A ChIP-seq, two independent ChIP experiments were performed in two
NIPBL-mutated CdLS individuals (Patient 3 and Patient 4) and one healthy
individual using anti-SMC1A rabbit polyclonal antibody73. Cells were cross-linked
with 1% formaldehyde, which was added to the medium for 15 min at room
temperature. After a quenching step with 0.125 M glycine, fixed cells were washed
twice with 1× PBS, pelleted, and lysed in lysis buffer (1% SDS, 10 mM EDTA, and
50 mM Tris-HCl, pH 8.1) containing 1 μM PMSF and protease inhibitors (Roche)
for 1 h at 4 °C. Cells were then sonicated using the Covaris system (shearing time
20 min, 20% duty cycle, intensity 10, 200 cycles per burst, and 30 s per cycle) in a
1 ml volume. Magna-beads A+G (Pierce) and 8 µl of antibody against SMC1A
were bound for 3–4 h at 4 °C in PBS, added to the chromatin (250 µg diluted four
times with buffer TE 0.5% SDS) and incubated overnight at 4 °C. Immunopreci-
pitated chromatin was washed three times with wash buffer1 (50 mM Hepes pH
7.5, 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate,
0.1% SDS, 1 mM PMSF) and twice with wash buffer2 (10 mM Tris pH 8, 0.25M
LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA, 1 mM PMSF). The
DNA was eluted from beads with 200 µl of elution buffer (1% SDS, 10 mM EDTA
and 50 mM Tris-HCl, pH 8.1) and incubated for 45 min at 65 °C. To carry out
reverse-cross-linking the supernatant was incubated for 4 h at 65 °C, and then
treated with 7.5 µl of proteinase K (20 mg/ml) and 1 µl of RNAse A (Sigma) for 1 h
at 37 °C. DNA was purified using the NucleoSpin Gel and PCR Clean-up kit
(Macherey-Nagel). Around 5 ng of immunoprecipitated chromatin in each sample
was used for library preparation.
For NIPBL ChIP-seq, cycling cells from Patient 3 CdLS-derived fibroblasts and
one healthy control were used for calibrated ChIP-seq (Spike-in ChIP-seq)
experiments. For the spike, 5% of sonicated chromatin from mouse embryonic
stem (ES) cells was added to the human chromatin. Protein-G beads (70 µl, Life
Technologies) and 10 µl of antibody against NIPBL (3B9, Novus Biological
H00025836-M01) were used for immunoprecipitation.
ChIP-seq fastq files were trimmed with Trim Galore (v0.4.5) and aligned to the
hg19 reference genome with Bwa mem (v0.7.17) and Samtools (v1.7). Reads with
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mapping quality ≤3 were removed. Duplicated reads were also removed using the
Picard (v2.8.15) tool MarkDuplicates. MaNorm (v1.0) software was used to identify
differential enrichment regions between Patient and Control samples. A
significance threshold of −log10 adjusted value of p > 2 was used to identify regions
differentially enriched between samples.
The mouse spike-in chromatin was used to normalize across NIPBL samples55.
Briefly, reads were first aligned to a combined reference genome consisting of the
human hg19 and the mouse mm10 genome assemblies. Then, for each sample,
those reads mapping uniquely to mm10 were quantified. Since the proportion of
mouse spike-in DNA was the same across samples, the differences in mm10 read
coverage between samples were used to normalize the NIPBL sample signal.
Specifically, the bam files with the greatest number of uniquely mapped reads to
mm10 were downsampled so that all samples would yield the same amount of
unique mm10 reads. The R (v3.4.4) package NCIS was used to calculate a scaling
factor between IP and INPUT samples that was used by the peak calling software
Macs2 (v2.1.1.20160309) to sensitively call peaks across all bam files. A threshold of
LFC > 5 was used to filter out dubious NIPBL peaks.
All peaks were annotated using Homer (v3.12) software and custom R scripts.
Specifically, the distance to TSS and gene names were annotated using Homer, and
the distance to CpG and Enhancers were annotated using R’s GRanges methods.
CpG island information was obtained from UCSC queries using rtracklayer and
Enhancer information was obtained from the Enhancer Atlas database (http://
www.enhanceratlas.org/).
ChIP signal at specific genomic locations was obtained using custom scripts in
R. Specifically, for each called peak, a ±500 bp window was opened around the
peak’s midpoint. The generated data were visualized in R using custom scripts.
Venn diagrams were generated using the online resource http://bioinformatics.psb.
ugent.be/webtools/Venn/.
ChIP-seq validation by ChIP-qPCR. Cells were collected, cross-linked, and sonicated
as described above and chromatin immunoprecipitation was performed following the
protocol of the iDeal ChIP-seq kit for transcription factors (Diagenode). The immu-
noprecipitated DNA was used to perform qPCR with the SYBR Premix Ex Taq
(Takara) and the Light Cycler 480 instrument (Roche). The relative amount of each
amplified fragment was normalized with respect to the amplification obtained from
input DNA. Primers were designed using the Primer3 web site94.
DNA methylation analysis. Genomic DNA was obtained from CdLS-derived
fibroblasts with a NucleoSpin DNA RapidLyse Kit (Macherey-Nagel). All DNA
samples were quantified by the fluorometric method (Quant-iT PicoGreen dsDNA
Assay, Life Technologies), and assessed for purity by NanoDrop (Thermo Scien-
tific) 260/280 and 260/230 ratio measurements. Six hundred nanograms of DNA
were processed using the EZ-96 DNA Methylation kit (Zymo Research) following
the manufacturer’s recommendations for Infinium assays.
Seven microliters of DNA were processed following the Illumina Infinium HD
DNA Methylation Assay Protocol95. Infinium 450 K DNA Methylation Array was
hybridized. Data were analyzed with R (version 3.4.2) using minfi (1.23.4).
Quantile and functional normalization were performed using the minfi96 package,
following the author’s guidelines. The DNA methylation score of each CpG is
represented as a β-value. We excluded possible sources of biological and technical
biases that could have affected the results (probes located on X/Y chromosomes,
SNPs, etc.). We also evaluated the detection probabilities (comparing signals
intensities against background noise) for all CpGs and excluded those CpGs with
values of p > 0.01 in more than one sample. For the differential DNA methylation
analysis, a linear model was derived using minfi in R for all the CpGs. The resulting
probabilities were corrected for multiple testing (FDR).
DNA Methylation was validated by bisulfite pyrosequencing (PyroMark Q96
System). Five DMPs for HOXC4, 5, 6 and seven DMPs for HOXB3 were tested.
Means and SEMs were calculated for all the DMPs within a promoter and
represented as DMRs.
In silico intra-TAD loops prediction. We adapted the computational method
proposed by Matthews and Waxman77 to predict TADs from ChIP-seq data. This
tool focuses on two main TADs characteristics: (i) TAD boundaries or anchors are
enriched with both CTCF and cohesin binding and (ii) the convergent orientation
of both TAD CTCF anchors. To identify CTCF motifs in ChIP-seq regions and
their corresponding orientation we used FIMO program (v5.1.0) using ChIP-seq
GEO data for CTCF (GSM935404). Our experimental control and two patients
(Patient 3 and Patient 4) SMC1A ChIP-seq datasets were used. Computational tool
was executed with the minimum proportion default value (40%). This parameter
defines the minimum cohesin and CTCF anchors to be considered for identifying a
first list of putative loops. Resulting TADs lists were reduced after removing
redundant TADs. Two TADs were considered redundant if they shared the same
TAD upstream anchor and showed a minimum reciprocal overlapping of 98%. The
wider TAD was kept in the final TADs list. Prediction tool scored TADs based on
the respective Macs2 ChIP-seq peak strength and FIMO CTCF motif occurrence
score in regions of interest. To assign combined TAD scores, we combined cohesin
and CTCF ChIP-seq scores by means of their geometric mean.
To compare the in silico prediction tool with experimental published TADs
we used the high-resolution Hi-C data reported by Rao et al.78 in IMR90 cell
lines (GEO dataset GSE63525). We scanned all the loop anchors searching for a
CTCF motif (JASPAR4 motif MA0139.1) using FIMO as in the prediction
method selecting the experimental loops with CTCF motif at both anchors. We
quantified the in silico and experimental TADs that reciprocally overlapped in a
95% minimum and categorized them as a complete match. We considered a
partial match when (a) an in silico TAD fully included an experimental TAD
(include) or vice versa (inside), and (b) in silico and experimental TADs partially
overlapped. The rest of in silico or experimental TADs were labeled as
unmatched TADs. Given a TAD, we selected the partial match with the highest
overlap percentage if several hits were retrieved. Next, we compared the in silico
prediction tool in control and CdLS-derived samples. We categorized TADs
derived from the control sample as complete match, partial match, or
unmatched TAD as above and compared them to the integrated patients TADs
list. TADs scores distributions were compared among the three categories and
statistically tested using a Wilcoxon test.
For comparison and visualization purposes, we used bedtools (v2.26.0) utilities,
phyton (v2.7.17), ChIPpeakAnno (v3.18.1), GenomicRanges (v1.36.0), ggplot2
(v3.3.2), ggubr (v0.2.3), and Bioconductor (v3.9.0) R (v3.6.3) packages.
3C-qPCR studies. The chromosome conformation capture assay was performed as
described in Williamson et al.97 with some modifications. Approximately 8 × 106
cells were fixed with 1% formaldehyde for 10 min at room temperature. Cross-
linking was stopped with 125 mM glycine for 5 min followed by two washes with
cold PBS. Cells were centrifuged at 1000 × g for 5 min at 4 °C, supernatants were
removed, and cell pellets were flash-frozen on dry ice. Cells were incubated for 30
min at 4 °C in 200 µl of lysis buffer (10 mM Tris pH 8.0, 10 mM NaCl, 0.2% NP-40,
supplemented with Complete protease inhibitor cocktail (Roche)). Chromatin was
then centrifuged at 2000 × g for 5 min. Supernatants were removed, pellets were
washed twice with 100 µl of 1X HindIII buffer (New England Biolabs), and the
chromatin pellet was resuspended in 400 µl of 1X HindIII buffer and incubated for
10 min at 65 °C with 0.1% SDS. Forty-four microliters of 10% Triton X-100 was
added before overnight digestion with 400 U of HindIII at 37 °C. The restriction
enzyme was then inactivated by adding 86 µl of 10% SDS and incubating for 30 min
at 65 °C. Samples were then diluted into 7.5 ml of ligation mix (750 µl of 10%
Triton X-100, 750 µl of 10X ligation buffer, 80 µl of 10 mg/ml of BSA, 80 µl of 100
mM ATP, 3000 cohesive end units of T4 DNA ligase) and incubated for 2 h at 16 °
C and 30 min at RT. 3C libraries were incubated overnight at 65 °C with 25 µl of
Proteinase K (20 mg/ml) and an additional 25 µl of Proteinase K the following day
for 2 h. The DNA was purified by two phenol–chloroform extractions and pre-
cipitated with 0.1 vol of 3 M NaOAc (pH 5.2) and 2.5 vol of cold EtOH. After at
least 1 h at −80 °C, the DNA was centrifuged at 20,000 × g for 25 min at 4 °C, and
the pellets were washed with cold 70% EtOH twice. DNA was resuspended in 400
µl of TE (pH 8.0) and transferred to 1.5 ml tubes for another phenol–chloroform
extraction and precipitation with 40 µl of 3 M NaOAc (pH 5.2) and 1.1 ml of cold
EtOH. DNA was recovered by centrifugation and washed five times with cold 70%
EtOH. Pellets were then dissolved in 100 µl of TE (pH 8.0) and incubated with 1 µl
of 10 mg/ml RNase A for 15 min at 37 °C. DNA was used to perform a qPCR
reaction to validate six predicted TADs: TAD1 (chr6:39833046–3986
0745), TAD2 (chr7:30588369–30780468), TAD3 (chr3:48506691–48647407),
TAD4 (chr19:41055101–41140816), TAD5 (chr4:8268881–8405291), and TAD6
(chr12:54
399697–54601972). Four 100 bp genomic regions without HindIII restrictions sites
inside were used to normalize the data.
Statistical analysis. Statistical significance was tested by analysis of the unpaired
two-tailed Student’s t-test (GraphPad Prism (v5). Values of p < 0.05 were con-
sidered statistically significant, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
Data availability
The data that support this study are available from the corresponding authors upon
reasonable request. ChIP-seq data generated in the course of this work have been
deposited in the Gene Expression Omnibus (GEO) under the accession number
GSE145966. Encode data for RAD21 (ENCFF361FUX) and MNase (ENCFF000VLK),
GEO data for CTCF (GSM733672) and DNase (GSM816655), and Enhancer Atlas
database for enhancer information (http://www.enhanceratlas.org/) were used for Fig. 5
and Supplementary Fig. 7. GEO data for CTCF (GSM935404) and the high-resolution
Hi-C data for IMR90 cell lines (GSE63525) were used for the intra-TAD prediction tool
for Fig. 7 and Supplementary Fig. 8. Other data supporting the findings of this study are
available within the paper, its supplementary information files, and the source data
file. Source data are provided with this paper.
Code availability
The custom scripts generated during the current study are available from https://
bitbucket.org/qgenomics/smc1a-nipbl.
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